Vertex Pharmaceuticals (VRTX)
NASDAQ: VRTX
· Real-Time Price · USD
387.02
-1.92 (-0.49%)
At close: Aug 26, 2025, 3:59 PM
385.60
-0.37%
After-hours: Aug 26, 2025, 04:37 PM EDT
-0.49% (1D)
| Bid | 383.7 |
| Market Cap | 99.23B |
| Revenue (ttm) | 11.42B |
| Net Income (ttm) | 3.64B |
| EPS (ttm) | 14.07 |
| PE Ratio (ttm) | 27.51 |
| Forward PE | 19.11 |
| Analyst | Buy |
| Ask | 390 |
| Volume | 1,822,864 |
| Avg. Volume (20D) | 1,636,642 |
| Open | 387.00 |
| Previous Close | 388.94 |
| Day's Range | 383.64 - 390.54 |
| 52-Week Range | 362.50 - 519.88 |
| Beta | 0.44 |
About VRTX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol VRTX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for VRTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Vertex Pharmaceuticals is scheduled to release its earnings on
Nov 3, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
+2.85%
Vertex Pharmaceuticals shares are trading higher a...
Unlock content with
Pro Subscription
3 weeks ago
-20.6%
Vertex Pharmaceuticals shares are trading lower following the release of its Q2 financial results. Additionally, the company announced results from its Vx-993 Phase 2 trial. Additionally, several firms cut their respective price targets on the stock.
1 hour ago · https://247wallst.com
Nasdaq Composite Live: All Eyes are on Nvidia Earnings this WeekLive Updates Live Coverage Has Ended Goldman Sachs just reiterated its buy rating on Nvidia 8:55 am Just this morning, analysts at Goldman Sachs reiterated a buy rating on Nvidia, ahead of earnings. “...
